跳至主導覽
跳至搜尋
跳過主要內容
長庚大學學術能量集萃 首頁
說明與常見問題
English
中文
首頁
學者概覽
研究單位
研究產出
研究計畫-專案
設備
獎項
活動
新聞/媒體
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
陳 芳萍
臨床教授
,
醫學系
電子郵件
D000000116
cgu.edu
tw
h-index
h10-index
h5-index
1730
引文
25
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
614
引文
14
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
257
引文
7
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1991 …
2024
每年研究產出
概覽
指紋
網絡
研究計畫-專案
(4)
研究產出
(103)
相近領域學者
(6)
指紋
查看啟用 Fang-Ping Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Patient
100%
Postmenopause
81%
Therapeutic Procedure
67%
Case Report
44%
Pregnancy
41%
Woman
40%
Bone Density
36%
Neurectomy
31%
Osteoporosis
31%
Spine Fracture
31%
Estrogen
30%
Dysmenorrhea
27%
Chemoradiotherapy
26%
Hormone Substitution
25%
Association
23%
Diagnosis
23%
Serum
23%
Prenatal Diagnosis
23%
Fracture
22%
Hip Fracture
21%
Estrogen Receptor
21%
Dual-Energy X-Ray Absorptiometry
19%
Sarcopenia
19%
Osteoblast
18%
Surgery
18%
Risk Assessment
18%
Hormone Therapy
17%
Assessment
17%
Muscle
17%
Age
17%
Evaluation Study
17%
Analysis
17%
Fetus
16%
Cancellous Bone
16%
Cardiovascular Risk
16%
Gestagen
16%
Growth
15%
Head and Neck Cancer
15%
Estradiol
15%
Pelvis Pain Syndrome
15%
Second Trimester Pregnancy
14%
Inpatient
13%
Messenger RNA
13%
Endometriosis
13%
Combination Therapy
12%
Infant
12%
Hemostat
12%
Ascites
12%
Mortality
12%
FRAX
12%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
36%
Estrogen Receptor
28%
Estrogen
25%
Progestin
21%
Replacement Therapy
21%
Phthalic Acid
21%
Hormone
19%
Diethylstilbestrol
19%
Endocrine Therapy
17%
Hip Fracture
16%
Phytoestrogen
15%
Normal Human
15%
Osteoporosis
15%
Fracture
11%
Apoptosis
11%
Cardiovascular Risk
11%
High Density Lipoprotein Cholesterol
11%
Incidence
10%
Medroxyprogesterone Acetate
10%
Comorbidity
10%
Cell Cycle
10%
25 Hydroxyvitamin D
10%
Lipid
10%
Phthalic Acid Dibutyl Ester
9%
Phthalic Acid Benzyl Butyl Ester
9%
Progesterone
9%
Hemostatic Agent
8%
Messenger RNA
8%
Low Density Lipoprotein Cholesterol
8%
Protein
8%
Cell Proliferation
7%
Cholesterol
7%
Cardiovascular Disease
7%
Resveratrol
7%
Quercetin
7%
Phthalic Acid Bis(2 Ethylhexyl) Ester
7%
Lipoprotein
7%
Alkaline Phosphatase
7%
Genistein
7%
Tumor Growth
6%
Conjugated Estrogen
6%
Menopausal Syndrome
6%
Caspase 3
6%
Breast Tumor
6%
Estrogen Receptor Beta
5%
Bisphosphonic Acid Derivative
5%
Osteosarcoma
5%
Steroid Receptor
5%
Transdermal
5%
Fragility Fracture
5%
Nursing and Health Professions
Osteoporosis
51%
Woman
39%
Fracture
32%
Bone Density
21%
Hip Fracture
19%
Spine Fracture
16%
Control
16%
Incidence
16%
Hormonal Therapy
15%
Dual Energy X Ray Absorptiometry
15%
Patient
14%
Estrogen
12%
Prevention
12%
Breast Density
10%
Orthopedic Software
10%
Combination Therapy
9%
Diagnosis
7%
Analysis
7%
Fragility Fracture
7%
Bone Mass
6%
Body Composition
6%
Quality of Life
6%
Breast Cancer
5%
Consensus
5%
Gestagen
5%
Cohort Analysis
5%
Head and Neck Cancer
5%
Menopausal Syndrome
5%
Chemotherapy
5%
Open-Label Trial
5%
Cardiovascular Disease
5%
Infusion
5%
Sarcopenia
5%
Systematic Review
5%
Precancer
5%
Metabolic Syndrome X
5%
Prediction
5%
Syndrome
5%
Age Related Macular Degeneration
5%
Endometriosis
5%
Danazol
5%
Estradiol Blood Level
5%
Compression Fracture
5%
Tuberculous Peritonitis
5%
Dexamethasone
5%
X Ray Film
5%
Myalgia
5%
Grip Strength
5%
Zoledronic Acid
5%
Practice Guideline
5%
